Abstract:Background Over the past three decades, with substantial changes in lifestyle, the tendency to gain weight has increased, which is resulting in significant consequences affecting an individual's well-being. The fat mass and obesity-associated (FTO) gene is involved in food intake and energy expenditure and plays a crucial role in regulating homeostasis and controlling energy expenditure by hindering signals that generate from the brain. Edible seaweeds have been shown to enhance satiety owing to their health benefits. Methods Extensive screening of plant-derived anti-obesity compounds and seaweed compounds was conducted and validated for ADME properties and toxicity prediction. Further, the top ranked compounds were docked against the FTO protein to identify potential inhibitors and were subjected to molecular dynamic simulation studies to understand the binding stability of ligand protein complex. Finally, MM/PBSA studies were performed to calculate the binding free energy of the protein-ligand complexes. Results Through the virtual screening of 1,210 compounds, 443 compounds showed good docking scores less than −7.00 kcal/mol. Drug likeness screenings of 443 compounds showed that only 369 compounds were in accordance with these properties. Further toxicity prediction resulted in 30 non-toxic compounds. Molecular docking studies revealed four top ranked marine compounds. Finally, RL074 (2-hydroxyluzofuranone B) and RL442 (10-acetoxyangasiol) from marine red alga Laurencia sp showed good stability from molecular dynamic simulation studies. MM/PBSA results revealed that BT012 (24ε-hydroperoxy-6β-hydroxy-24-ethylcholesta-4,-28(29)-dien-3-one), an oxygenated fucosterol from brown alga Turbinaria conoides, possessed higher binding energy. Hence, with all the data obtained it could be concluded that three seaweed compounds, BT012, RL074 and RL442, may act as a potential anti-obesity lead compound in targeting FTO.

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

A Novel Inhibitor of the Obesity-Related Protein FTO.

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Crystal Structure of the FTO Protein Reveals Basis for Its Substrate Specificity

Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors

Identification of Natural Compound Radicicol As a Potent FTO Inhibitor.

Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases

Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1

FTO gene polymorphisms and obesity risk in Chinese population: a meta-analysis

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Fluorescein Derivatives As Bifunctional Molecules for the Simultaneous Inhibiting and Labeling of Fto Protein

A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities

Lose weight with traditional chinese medicine? Potential suppression of fat mass and obesity-associated protein.

Identification of Specific N 6 -Methyladenosine RNA Demethylase FTO Inhibitors by Single-Quantum-Dot-Based FRET Nanosensors

Computational study of potential inhibitors for fat mass and obesity-associated protein from seaweed and plant compounds

From Hit to Lead: Structure-based Discovery of Naphthalene-1-sulfonamide Derivatives As Potent and Selective Inhibitors of Fatty Acid Binding Protein 4.

Polymorphism in 5 ' Regulatory Region of the Porcine Fat Mass and Obesity Associated (fto) Gene is Associated with Intramuscular Fat Content in A Jinhua X Pietrain F-2 Reference Population

Fucoidans from Pearsonothuria Graeffei Prevent Obesity by Regulating Intestinal Lipid Metabolism and Inflammation Related Signalling Pathways

Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors

Structure‐Activity Relationships of 2‐(Arylthio)benzoic Acid FTO Inhibitors

Comprehensive mutations analyses of FTO (fat mass and obesity-associated gene) and their effects on FTO’s substrate binding implicated in obesity